We are thrilled to announce that Bicycle has won a 2018 World ADC Award for Best New Drug Developer.

This award honors a company in the drug conjugate field that has made strong progress advancing its preclinical pipeline. It acknowledges those who push the boundaries to dedicate their careers and companies to the pursuit of fighting cancer. In addition to Bicycle’s lead candidate BT1718, which entered the clinic in partnership with Cancer Research UK this year, our team is working to advance a broad pipeline of Bicycle conjugates.

At last year’s World ADC Awards, Bicycle received the award of Best Platform Technology, and scientific founder Sir Greg Winter received a lifetime achievement award. Our team is celebrating the tremendous strides we have made in the short time since then.